News Overview

Operating margins were healthy and steady at 30.54%, compared to 30% in the same quarter last year.

EBITDA margins have increased considerably, at 26.2% in Q4 FY25, compared to 15.6% in the corresponding quarter of last year

The medication is also prescribed to lower the risk of another heart attack in individuals with a past history of myocardial infarction and hyperlipidaemia

This regulatory sanction is under the Payment and Settlement Systems Act, 2007, applicable to digital transaction platforms and payment service providers in India.

EBITDA were ₹559.6 crore for the quarter ended March 2025, down 10.7% from ₹626.6 crore in the same quarter a year ago.

Revenue during Q4FY25 rose by 4.4% at ₹1,530.6 crore compared with ₹1,466.5 crore witnessed during Q4FY24.

EBITDA went down 6.3% YoY to ₹231.3 crore in Q4FY25 from ₹246.9 crore for the same quarter last year

On approval, the firm will allot up to 3,000 NCDs of face value ₹10 lakh each.

EBITDA margin also rose to 32.2%, compared to 30.9% last year corresponding quarter

Third-party cargo represented 49% of total, up from 40% in FY24, the result of greater reliance on non-captive business.